
2024 Fall Clinical Dermatology Conference for PAs and NPs Coverage Recap
Catch up on a weekend full of clinical pearls from the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.
To stay up-to-date with the latest dermatology news, sign up to receive our
Improvements persisted through the 12-week post-treatment follow-up, indicating sustained efficacy even after discontinuation of dupilumab.
Four leaders in HS treatment and care put a spotlight on the latest clinical trial data and treatment techniques.
Terry Arnold, PA-C, shared his journey and advice for PAs and NPs looking to transition out of a clinical practice.
Significant improvements were observed in EASI scores across all anatomical regions, regardless of patient age or specific body region.
Marc Serota, MD, provided clinical pearls to consider for patients on biologics, particularly dupilumab.
Raj Chovatiya, MD, PhD, takes a deep dive in the challenges, solutions, and further research needed to treat seborrheic dermatitis.
James Song, MD, discusses the current treatment landscape, genetic and immunological influences, and the role of oral minoxidil in alopecia areata.
Ben Lockshin, MD, FAAD, delves into the new generation of oral psoriasis therapies to enhance patient quality of life.
The trial results indicated 3 significant improvements across all AHFD subtypes with dupilumab treatment compared to placebo.
Jason Hawkes, MD, MS, detailed each of the kinases' association with different cytokine receptors and biological functions.
James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.
Lockshin shared his approach to continuing biologic therapies into pregnancy with informed timing adjustments.
Jason Hawkes, MD, MS, breaks down boxed warning pros and cons and research addressing several boxed warnings.
The country's only double-board certified pediatric and cosmetic dermatologist shared what he learned from 5 unique patient cases this year.
James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.
Jason Hawkes, MD, MS, gives an overview of what clinicians need to know today about this rare condition.
Raj Chovatiya, MD, PhD, focused on understanding JAK inhibitors, discussing their clinical use and safety profiles for effective patient communication.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















